Entera Bio Ltd. (ENTX)Healthcare | Biotechnology | Jerusalem, Israel | NasdaqCM
2.49 USD
-0.16
(-6.038%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 2.50 +0.01 (0.402%) ⇧ (Oct. 13, 2026, 4:25 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 4:57 a.m. EDT
The immediate outlook is clouded by a stark divergence between the stock's technical breakout and the market's fear of a reversal. While the price recently surged past key averages, triggering headlines about a 'breakout,' the options chain screams caution. The sheer volume of new put buying at the $3.00 level—significantly higher than existing open interest—suggests smart money is betting against a continuation of this rally, likely fearing the dilution risks associated with the recent $275 million private placement or a potential stumble in Phase 3 funding. Fundamentally, the investment case remains precarious. The company is burning significant cash with negative free cash flow and no earnings, trading at a premium to its book value despite having no sales revenue yet. The analyst consensus is a 'strong buy' with a target near $9.75, but this relies entirely on the success of their pipeline rather than current profitability. The balance sheet, while currently liquid, faces the threat of aggressive dilution to fund operations. Until there is concrete proof of commercial viability or a clear path to profitability without excessive capital raising, the risk-reward profile leans heavily toward downside protection. The recent price spike appears to be a speculative reaction to news flow rather than a sustainable trend supported by fundamentals. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.039583 |
| AutoETS | 0.039852 |
| AutoTheta | 0.039865 |
| MSTL | 0.053520 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 1.46 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 1.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.849 |
| Market Cap | 432,847,328 |
| Forward P/E | -4.53 |
| Beta | 1.41 |
| Website | https://enterabio.com |
As of Oct. 10, 2026, 4:57 a.m. EDT: Speculators are positioning aggressively for a downside event, evidenced by massive put volume (129 contracts) at the $3.00 strike for the nearest expiration, which exceeds open interest. This 'new flow' suggests traders are hedging against a failure to sustain the recent breakout or a regulatory setback. Conversely, call activity is concentrated further out at the $4.00 strike, indicating a speculative bet on a continued rally to test resistance, but the immediate sentiment is defensive.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.043307066 |
| Address1 | Kiryat Hadassah Minrav Building |
| Address2 | 5th Floor |
| All Time High | 10.16 |
| All Time Low | 0.472 |
| Ask | 3.12 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 628,800 |
| Average Daily Volume3 Month | 1,851,118 |
| Average Volume | 1,851,118 |
| Average Volume10Days | 628,800 |
| Beta | 1.407 |
| Bid | 1.88 |
| Bid Size | 2 |
| Book Value | 0.147 |
| City | Jerusalem |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.49 |
| Current Ratio | 8.981 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.65 |
| Day Low | 2.435 |
| Debt To Equity | 5.849 |
| Display Name | Entera Bio |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,600,000 |
| Earnings Timestamp Start | 1,794,600,000 |
| Ebitda | -14,369,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -29.246 |
| Enterprise Value | 420,239,168 |
| Eps Forward | -0.55 |
| Eps Trailing Twelve Months | -0.36 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.9021 |
| Fifty Day Average Change | -0.41210008 |
| Fifty Day Average Change Percent | -0.14200065 |
| Fifty Two Week Change Percent | 4.3307066 |
| Fifty Two Week High | 4.2 |
| Fifty Two Week High Change | -1.7099998 |
| Fifty Two Week High Change Percent | -0.40714282 |
| Fifty Two Week Low | 0.91 |
| Fifty Two Week Low Change | 1.5799999 |
| Fifty Two Week Low Change Percent | 1.7362636 |
| Fifty Two Week Range | 0.91 - 4.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,530,192,600,000 |
| Float Shares | 126,474,913 |
| Forward Eps | -0.55 |
| Forward P E | -4.5272727 |
| Free Cashflow | -6,684,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 20 |
| Fullday Change | -0.1500001 |
| Fullday Change Percent | -5.660381 |
| Fullday Price | 2.49 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | 0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05475 |
| Held Percent Institutions | 0.3411 |
| Implied Shares Outstanding | 173,834,271 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel. |
| Long Name | Entera Bio Ltd. |
| Market | us_market |
| Market Cap | 432,847,328 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_106997294 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -17,033,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 489,125,672 |
| Number Of Analyst Opinions | 4 |
| Open | 2.65 |
| Operating Cashflow | -10,889,000 |
| Operating Margins | 0.0 |
| Phone | 972 2 532 7151 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.40160605 |
| Post Market Price | 2.5 |
| Post Market Time | 1,791,923,110 |
| Previous Close | 2.65 |
| Price Hint | 4 |
| Price To Book | 16.938776 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 5.425 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.16 |
| Regular Market Change Percent | -6.03774 |
| Regular Market Day High | 2.65 |
| Regular Market Day Low | 2.435 |
| Regular Market Day Range | 2.435 - 2.65 |
| Regular Market Open | 2.65 |
| Regular Market Previous Close | 2.65 |
| Regular Market Price | 2.49 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 754,970 |
| Return On Assets | -0.45981 |
| Return On Equity | -1.3892 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 173,834,271 |
| Shares Percent Shares Out | 0.0138 |
| Shares Short | 2,403,597 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 885,945 |
| Short Name | Entera Bio Ltd. |
| Short Percent Of Float | 0.014400001 |
| Short Ratio | 5.8 |
| Source Interval | 15 |
| Symbol | ENTX |
| Target High Price | 11.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 9.75 |
| Target Median Price | 9.5 |
| Total Cash | 11,309,000 |
| Total Cash Per Share | 0.065 |
| Total Debt | 425,000 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.36 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.82265 |
| Two Hundred Day Average Change | 0.66735005 |
| Two Hundred Day Average Change Percent | 0.36614275 |
| Type Disp | Equity |
| Volume | 754,970 |
| Website | https://enterabio.com |
| Zip | 9,112,002 |